Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04254549
PHASE2

Rifaximin in Patients With Diabetic Gastroparesis

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Official title: Evaluating the Therapeutic Efficacy of Rifaximin in Patients With Diabetic Gastroparesis Using Bloating as the Primary Endpoint.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

5

Start Date

2019-06-14

Completion Date

2025-04-11

Last Updated

2026-06-22

Healthy Volunteers

No

Interventions

DRUG

Rifaximin

550 mg by mouth three times daily for 14 days

DRUG

Placebo

By mouth three times daily for 14 days

Locations (1)

Mayo Clinic in Florida

Jacksonville, Florida, United States